Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

Zachary R. Chalmers,Siraj M. Ali,Robert S. Ohgami,Paulo Vidal Campregher,Garrett M. Frampton,Roman Yelensky,Julia Andrea Elvin,Norma Alonzo Palma,Rachel L. Erlich,Jo Anne Vergilio,Juliann Chmielecki,J.S. Ross,Phillip J. Stephens,Hermann R,V.A. Miller,Miles Cr

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

2015

Zachary R. Chalmers
Siraj M. Ali
Robert S. Ohgami
Paulo Vidal Campregher
Garrett M. Frampton
Roman Yelensky
Julia Andrea Elvin
Norma Alonzo Palma
Rachel L. Erlich
Jo Anne Vergilio
Juliann Chmielecki
J.S. Ross
Phillip J. Stephens
Hermann R
V.A. Miller
Miles Cr

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

Keywords:

Immunology
Cancer research
Myeloid Neoplasm
PDGFRA
Eosinophilia
Imatinib
Medicine
Leukemia
Myeloid
imatinib mesylate
PDGFRB
Myeloproliferative Disorders
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations